DETERMINED

Natalie is Chief Executive Officer (CEO) of Third Harmonic Bio. She has more than 20 years of executive leadership, business development, corporate strategy, and commercial experience gained in a range of therapeutic areas.

Prior to Third Harmonic Bio, Natalie served as President and CEO of Audentes, an Astellas company. She joined the company as Senior Vice President (SVP) and Chief Operating Officer (COO) in August 2015 and was subsequently promoted to President and COO in May 2018, and then to President and CEO in January 2020. Prior to joining Audentes, Natalie served as SVP, Corporate Development at Hyperion Therapeutics, Inc. (acquired by Horizon Pharma in 2015). Before that, she provided executive-level strategy and business development advisory services to a number of privately held biopharmaceutical companies. Earlier in her career, Natalie served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc.

Natalie holds an A.B. in human biology from Stanford University and an M.A. in molecular, cellular, and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute predoctoral fellow.

Edward is the Chief Medical Officer (CMO) of Third Harmonic Bio where he oversees the clinical development strategy for the company. Edward has extensive experience in clinical development, translational medicine, and clinical strategy, including broad experience in early- to late-stage and post-marketing products.

Edward joined Third Harmonic Bio from Locanabio, where he served as CMO. Prior to Locanabio, Edward was Site Lead and Division Head of Medical and Development for Astellas Gene Therapies (formerly Audentes Therapeutics). Prior to Astellas’ acquisition of Audentes, he served as CMO and Senior Vice President of Audentes Therapeutics, where he led functions including clinical development and operations, medical affairs, regulatory, drug safety, and patient advocacy. Before Audentes, Edward served as CMO of Sangamo Therapeutics. Earlier in his career, he was a Medical Director at Genentech, Inc. (now a member of the Roche Group) where he led clinical development programs for XOLAIR® (omalizumab) for the treatment of chronic urticaria and allergic asthma.

Edward earned a M.D. from the University of California, San Francisco, completed his residency in Internal Medicine at the University of Michigan and his fellowship in Clinical Immunology and Allergic Diseases at Johns Hopkins School of Medicine. He earned a B.S. degree in biology from Duke University.

XOLAIR® is a registered trademark of Novartis AG.

Dennis has extensive experience across multiple therapeutic areas of drug discovery and development, with a particular focus in DMPK, preclinical safety assessment, clinical pharmacology, biomarkers, and modeling and simulation. In his role as Chief Non-Clinical Development Officer, he is responsible for leading the selection of high-quality development candidates, including toxicology, DMPK and translation functions. Prior to joining Third Harmonic Bio, Dennis served as Chief Development Officer of IFM Therapeutics, where he oversaw preclinical and clinical development, advancing multiple programs into early clinical development leading to three acquisitions by global pharmaceutical companies. Before IFM Therapeutics, he was Senior Vice President, Head of Preclinical Development at Vertex Pharmaceuticals, where he linked key preclinical translational groups, effectively progressed the pipeline, and bridged transition for discovery into development. Earlier in his career, he held positions of increasing responsibility in DMPK at Merck Research Laboratories.

He received his Ph.D. in medicinal chemistry at State University of New York, Buffalo, and was a Postdoctoral Fellow at Emory University.

Chris is a seasoned leader with a strong track record of advancing early targets to drug candidate identification and through clinical development. In his role as Chief Scientific Officer, he oversees the company’s scientific research strategy from discovery through preclinical proof-of-concept, IND filing, and also support early clinical development. Chris joined Third Harmonic Bio from Kronos Bio, where he was Chief Scientific Officer, responsible for the discovery functions, and played a key role in the company’s initial public offering and partnership with Genentech. Prior to Kronos, he served as an Entrepreneur-in-Residence at Third Rock Ventures, focusing on the launch of new biomedical companies. Earlier in his career, he served as Vice President, Head of Chemistry, of Forma Therapeutics, where he oversaw chemistry functions in support of discovery and early development. He began his career at Merck Research Laboratories where he held positions of increasing responsibility in discovery chemistry.

He received his Ph.D. in organic chemistry from University of Minnesota, Minneapolis, and was a NIH Postdoctoral Fellow in organic chemistry at Harvard University.

Jennifer Dittman joined Third Harmonic Bio in November 2022, as Vice President of Regulatory Affairs and was promoted to Chief Development Operations Officer in 2024. In her expanded role, she is responsible for regulatory affairs, program management, quality, and CMC. Prior to joining Third Harmonic Bio, Jennifer was Vice President of Regulatory Affairs and Medical Writing at Generation Bio, where she was responsible for platform and pipeline regulatory activities. Before Generation Bio, she held roles of increasing responsibility at Vertex Pharmaceuticals, most recently serving as Executive Director, Therapeutic Area Head, in Regulatory Affairs, where she helped set the global regulatory strategy for multiple pipeline products in development, including small molecule and gene therapy/editing programs. Earlier in her career, Ms. Dittman served in roles of increasing responsibility in Regulatory Affairs at bluebird bio and was Adjunct Faculty in the Regulatory Affairs program at Northeastern University.

She holds a M.S. in regulatory affairs for drugs, biologics, and medical devices from Northeastern University.

Chris Murphy is the Chief Financial and Business Officer at Third Harmonic Bio. In this role, he oversees strategic leadership and direction of the company’s finance, corporate strategy, and business development functions.

Chris brings extensive experience in business development, commercial operations, corporate strategy and investment banking in the biopharmaceutical industry to the company’s leadership team. He most recently served as a member of the leadership team that transformed Horizon Therapeutics PLC from a primary care-focused specialty pharmaceutical company with a market capitalization of approximately $800 million to a fully integrated, highly profitable rare disease-focused biopharmaceutical company, which was acquired by Amgen Inc. for $28 billion in October 2023. While at Horizon, Chris served in roles of increasing responsibility in business development and commercial operations. In business development, he was most recently Group Vice President, where he oversaw a number of strategic transactions and integrations. In commercial operations, Chris most recently served as Group Vice President, overseeing market access, sales and marketing operations, and analytics across Horizon’s portfolio of medicines, including during the preparation and initial launch of TEPEZZA^® (teprotumumab-trbw) for the treatment of thyroid eye disease. Earlier in his career, Chris held positions of increasing responsibility in the Life Sciences Investment Banking Group at JMP Securities LLC.

Chris earned a B.A. in Business Administration in Finance from the University of Notre Dame.

Julie Person is the Chief Administrative Officer at Third Harmonic Bio. She brings more than 20 years of experience in building biopharma organizations that align people practices with strategy to drive successful outcomes for patients and teams. In her role, Julie oversees human resources, corporate communications, and facilities.

Julie joined Third Harmonic Bio from Neumora Therapeutics, where she served as Chief People Officer and oversaw human resources and internal communications. Prior to Neumora, she was Head of Human Resources at Audentes Therapeutics and Sangamo Therapeutics, Inc. Prior to Sangamo, Julie was the Global Head of Talent Management at Shire Plc, where she played a key role in the integrations of both Baxalta International Inc. to Shire, and Shire into Takeda Pharmaceutical Company Ltd. Prior to Shire, she spent 12 years at McKesson Corp. in various HR roles of increasing responsibility.

Julie received her undergraduate degree in communications from Saint Mary’s College of California and completed the University of Michigan Ross School of Business Executive Leadership Program.